Loading
Tango Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$3.7B
No insider purchase over the last 90 days. The latest was filed 18 Nov 2024.
Tango Therapeutics, Inc.: what insiders have been doing
Every trade that managers of Tango Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. Over the twelve months to 18 October 2026, 32 filings were filed, from 13 insiders.
No insider bought on the market over the period, while 3 insiders filed 13 sales totalling €8.2M. Biggest ticket of the year: €4.2M, sold by Third Rock Ventures IV, L.P. and made public on 27 October 2025.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 32 filings, this issuer sits above that mark. Since 2022, the database holds 5 purchases and 47 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 62.4 m USD of revenue and -101.6 m USD of net income.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
101
Thresholds
n/a
Buy Volume
€8M
5 ops. · all time
Sell Volume
€68M
47 ops. · all time
Who traded when
BuySaleAdam Crystal10 sales
Third Rock Ventures IV, L.P.6 sales
Jessica Newcomb3 sales
Barry Douglas1 sale
Beckman Daniella1 sale
Boxer Capital Management, LLC1 sale
+3 other insiders
Since the insiders bought
- +115.2%Entry US$3.85 · Close at T+365 US$8.28
- -3.6%Entry US$7.26 · Close at T+365 US$7.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Tango Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$44.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.04
Analyst consensus
12 analystsStrong buy
US$24.00Target US$44.88(+104%)US$69.00
Income statement
RevenueUS$62.4M
EBITDA-US$109M-175% margin
Net income-US$101.6M-229.9% margin
Valuation
PER (forward)-13.3x
P/Book3.6x
Beta1.17
Balance sheet & cash
Market capUS$3.7B
Total debtUS$33.6M
Free Cash Flow-US$139.9M
Debt / Equity3%
Profitability & ownership
ROE-21.3%
ROA-13.0%
% insiders1.2%
% institutions128.7%
Last declaration on 5 October 2026
Declarations101 total
27,000 shares@ US$5.200.0036% mcap2.6% of flowCommon StockSEC:0001193125-26-414500:0
26,400 shares@ US$24.45470.016% mcap12.0% of flowCommon StockSEC:0001193125-26-414500:1
600 shares@ US$25.320.0004% mcap0.3% of flowCommon StockSEC:0001193125-26-414500:2
700 shares@ US$22.80290.0004% mcap8.0% of flowCommon StockSEC:0001193125-26-401327:0
5,100 shares@ US$23.96830.0029% mcap61.5% of flowCommon StockSEC:0001193125-26-401327:1
2,400 shares@ US$25.17180.0015% mcap30.4% of flowCommon StockSEC:0001193125-26-401327:2
15,231 shares@ US$22.33100.0% of flowCommonSEC144:0001950047-26-009747
27,000 shares@ US$5.200.0033% mcap3.0% of flowCommon StockSEC:0001193125-26-381853:0
27,000 shares@ US$22.3670.014% mcap12.9% of flowCommon StockSEC:0001193125-26-381853:1
27,000 shares@ US$5.200.0034% mcap3.0% of flowCommon StockSEC:0001193125-26-335002:0
5,267 shares@ US$26.78950.0034% mcap3.0% of flowCommon StockSEC:0001193125-26-335002:1
21,733 shares@ US$27.35090.014% mcap12.8% of flowCommon StockSEC:0001193125-26-335002:2
81,000 shares@ US$27.180.053% mcap100.0% of flowCommonSEC144:0001950047-26-007562
5,740 sharesCommon StockSEC:0001193125-26-279871:0
3,766,081 shares@ US$30.102.26% mcap100.0% of flowCommon StockSEC144:0001894038-26-000002
1,791,726 shares@ US$28.75641.02% mcap99.7% of flowCommonSEC144:0001950047-26-005968
4,446 shares@ US$30.000.0029% mcap0.3% of flowCommonSEC144:0001950047-26-005901
4,000 shares0Common StockSEC:0001193125-26-262205:0
38,460 shares@ US$5.200.0040% mcap4.2% of flowCommon StockSEC:0001193125-26-159747:0
38,460 shares@ US$25.000.019% mcap20.2% of flowCommon StockSEC:0001193125-26-159747:1
27,000 shares@ US$5.203.0% of flowCommon StockSEC:0001193125-26-140874:0
27,000 shares@ US$21.202912.2% of flowCommon StockSEC:0001193125-26-140874:1
12,000 shares@ US$5.201.3% of flowCommon StockSEC:0001193125-26-129990:0
20,251 shares@ US$15.006.5% of flowCommon StockSEC:0001193125-26-098443:0
25 of 101 declarations
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. It employs innovative approaches to identify and exploit the genetic vulnerabilities of tumor cells.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
